What is the best treatment approach to a patient with HGBCL with FISH translocation of BCL-6 and c-Myc given new classification of this entity?

The International Consensus Classification (ICC) and the 2022 WHO 5th Edition have sought to refine the approach to high-grade B-cell lymphomas (HGBL) with c-Myc and BCL-6 rearrangements. As the questionnaire astutely implies, the WHO now excludes cases with concurrent c-Myc and BCL-6 rearrangements...

I usually use dose-adjusted R-EPOCH in fit patients with normal EF.

Dose-adjusted EPOCH